Korean J Pediatr Infect Dis.  2012 Apr;19(1):12-18.

Antibiotic-Associated Diarrhea in 3 to 6 Month Old Infants with Febrile Urinary Tract Infections

• Won CB
• Kim MC
• Eun BW
• Sun YH
• Cho KH
• Tcha H
• Jeon IS

Abstract

PURPOSE
This study attempted to investigate the frequency, duration, and risk factors of antibiotic-associated diarrhea (AAD) in infants hospitalized due to febrile urinary tract infection (UTI). This is a basic research on the probiotics used in the prevention and treatment of AAD in infants.
METHODS
Medical records of the infants aged 3-6 months hospitalized in Gachon University Gil Hospital from January 2008 to September 2010 due to the febrile UTI were retrospectively reviewed. The episodes of loose or watery stool were investigated for frequency, onset, and duration. Those who had AAD and those who did not (non-AAD) were compared. The antibiotic regimens and the episodes of diarrhea were investigated in AAD group.
RESULTS
Total 147 infants were included. Fifty-four (36.7%) showed AAD. Intravenous third-generation cephalosporin (3rd CS) single therapy was used for 102 patients (69.4%), the 3rd CS and non-3rd CS combination therapy for 24 (16.3%), and non-3rd CS combination therapy for 21 (14.3%). There was no significant difference in the dose of cefotaxime between AAD and non-AAD group (P=0.601). According to the antibiotic therapies above, in AAD group, there was no significant difference in the onset and duration of diarrhea respectively (P=0.717, P=0.830). Although the frequency of diarrhea was higher for the 3rd CS and non-3rd CS combination therapy subgroup with 9.25+/-5.30 times/day than the other two subgroups (7.58+/-2.97 times/day in 3rd CS single therapy subgroup, 6.75+/-4.40 times/day in non-3rd CS combination therapy subgroup), there was no statistical significance (P=0.078).
CONCLUSION
AAD seems common to the infants aged 3-6 months with febrile UTI, regardless of regimen and amount of antibiotics in usual dosage. Further research on the effects of probiotics used in the prevention and treatment of AAD in infants is warranted.

Keyword

Urinary tract infection; Diarrhea; Antibiotics; Child

MeSH Terms

Aged
Anti-Bacterial Agents
Cefotaxime
Child
Diarrhea
Humans
Infant
Medical Records
Probiotics
Retrospective Studies
Risk Factors
Urinary Tract
Urinary Tract Infections
Anti-Bacterial Agents
Cefotaxime

Reference

1. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996. 4:430–435.

2. Park HS, Han DS. Management of antibiotics-associated diarrhea. Korean J Gastroenterol. 2009. 54:5–12.

3. Alam S, Mushtaq M. Antibiotic associated diarrhea in children. Indian Pediatr. 2009. 46:491–496.

4. Simakachorn N, Pichaipat V, Rithipornpaisarn P, Kongkaew C, Tongpradit P, Varavithya W. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr. 2000. 30:68–72.

5. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005. 21:583–590.

6. Jo YJ, Lee EJ, Choi KM, Eun YM, Yoo HJ, Kim CH, et al. Causative organisms of community acquired urinary tract infection and their antibiotic susceptibility at a secondary hospital in Korea. Korean J Pediatr Infect Dis. 2010. 17:30–35.

7. Bae EY, Lee SY, Jeong DC, Kang JH. Clinical characteristics and antibiotic resistance of urinary tract infections in children: Escherichia coli Versus Non-E. coli. Korean J Pediatr Infect Dis. 2010. 17:67–73.

8. Högenauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998. 27:702–710.

9. Kligler B, Hanaway P, Cohrssen A. Probiotics in children. Pediatr Clin North Am. 2007. 54:949–967.

10. Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007. 96:538–541.

11. Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2007. CD004827.

12. Floch MH, Walker WA, Guandalini S, Hibberd P, Gorbach S, Surawicz C, et al. Recommendations for probiotic use--2008. J Clin Gastroenterol. 2008. 42:Suppl 2. S104–S108.

13. Turck D, Bernet JP, Marx J, Kempf H, Giard P, Walbaum O, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003. 37:22–26.

14. Song HJ, Kim JY, Jung SA, Kim SE, Park HS, Jeong Y, et al. Effect of probiotic Lactobacillus (Lacidofil(R) cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. J Korean Med Sci. 2010. 25:1784–1791.

15. Jirapinyo P, Densupsoontorn N, Thamonsiri N, Wongarn R. Prevention of antibiotic-associated diarrhea in infants by probiotics. J Med Assoc Thai. 2002. 85:Suppl 2. S739–S742.

16. Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med. 2005. 257:78–92.